Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT06395753 Recruiting - Prostate Cancer Clinical Trials

A Dose Finding Study of Debio 4228 in Participants With Locally Advanced/Metastatic Prostate Cancer

Start date: June 2024
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.

NCT ID: NCT06395519 Recruiting - Breast Cancer Clinical Trials

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

ERADIC8
Start date: May 2024
Phase: Phase 1
Study type: Interventional

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

NCT ID: NCT06392737 Recruiting - Prostate Cancer Clinical Trials

Comparison of MRI Artificial Intelligence-guided cTB Versus Routine cTB in Prostate Cancer Diagnosis

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The goal of this multicenter clinical trial is to compare the cancer detection rates of MRI artificial intelligence-guided cTB (AI-cTB) and routine cTB, and explore the added value of using AI for the guidance of cTB. The main questions it aims to answer are: Does AI-cTB promote the accurate diagnosis and treatment of prostate cancer? What's the value of prostate MRI artificial intelligence assistant diagnosis system in developing the best scheme of prostate biopsy? What's the value of prostate MRI artificial intelligence assistant diagnosis system in predicting the pathological results of prostate targeted biopsy? What's the generalizability of the MRI artificial intelligence assistant diagnosis system? Researchers will compare the cancer detection rates of AI-cTB and routine cTB to explore the added value of using AI for the guidance of cTB. Participants will: Receive AI-cTB or routine cTB.

NCT ID: NCT06392295 Recruiting - Prostate Cancer Clinical Trials

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

OCEAN
Start date: August 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this prostate cancer research study is to learn about: 1. Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy; 2. Preserving quality of life after radiation therapy; 3. Leveraging imaging results from prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) scans to evaluate and manage disease progression.

NCT ID: NCT06389695 Recruiting - Prostate Cancer Clinical Trials

Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients

Start date: May 2024
Phase: Phase 1
Study type: Interventional

68Ga-NYM032 is a PSMA-targeting small-molecular radiotracer for PET/CT imaging of prostate cancer, which is needed for clinical trial to be conducted

NCT ID: NCT06385847 Recruiting - Prostate Cancer Clinical Trials

To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer

Start date: May 2024
Phase: Phase 2
Study type: Interventional

The GOMIMP will be a Prospective, Randomized, Cross-over Trial to Explore the Patient Preference for Goserelin Microsphere (Zoladex®) Versus Goserelin Implant (LY01005) in Patients of Prostate Cancer

NCT ID: NCT06380660 Recruiting - Breast Cancer Clinical Trials

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Start date: March 22, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.

NCT ID: NCT06378346 Recruiting - Prostate Cancer Clinical Trials

GU-01: Glycyrrhizin in Prostate Cancer

GU-01
Start date: May 2024
Phase: Phase 2
Study type: Interventional

This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer (PCa) who are candidates for surgery (radical prostatectomy)

NCT ID: NCT06375629 Recruiting - Prostate Cancer Clinical Trials

ES-HIFU, Prospective Data Collection of Patients Treated With Partial Gland HIFU Ablation for Prostate Cancer

ES-HIFU
Start date: April 20, 2023
Phase:
Study type: Observational

The objective of this study is to evaluate the clinical effectiveness and safety of treatment of prostate cancer in patients who have received a focal HIFU treatment using the Focal One medical device.

NCT ID: NCT06363435 Recruiting - Prostate Cancer Clinical Trials

AI-based Measurements of Tumour Burden in PSMA PET-CT

Start date: March 29, 2024
Phase:
Study type: Observational

The primary aim of the present study is to evaluate how automatically calculated (by an AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x SUVmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as the total tumour burden predicts overall survival (OS) in patients with prostate cancer (newly diagnosed and patients with biochemical recurrence).